-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 LlKJSE08jM9gBOpXFHJDlp9mkjALGfiVFkFUZ4Gt/Ef1cyjuuaGzPcyAGJsQ2mzA
 1KF8FxStafrxKVmY4/0phg==

<SEC-DOCUMENT>0001157523-08-009325.txt : 20081114
<SEC-HEADER>0001157523-08-009325.hdr.sgml : 20081114
<ACCEPTANCE-DATETIME>20081114064738
ACCESSION NUMBER:		0001157523-08-009325
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20081114
FILED AS OF DATE:		20081114
DATE AS OF CHANGE:		20081114

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ICON PLC  /ADR/
		CENTRAL INDEX KEY:			0001060955
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	333-08704
		FILM NUMBER:		081186956

	BUSINESS ADDRESS:	
		STREET 1:		BANK OF NEW YORK
		STREET 2:		48 WALL ST
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10286
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a5831439.htm
<DESCRIPTION>ICON PLC 6-K
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2008 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-size: 10pt; font-family: Times New Roman">
    <p style="text-align: center">
      <br>

    </p>
    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 14pt"><b>FORM 6-K</b></font><br><br><br><font style="font-size: 12pt"><b>SECURITIES
      AND EXCHANGE COMMISSION</b></font><br><br><br><font style="font-size: 12pt">Washington,
      D.C. 20549</font><br><br><br><font style="font-family: Times New Roman; font-size: 12pt"><b>Report
      of Foreign Private Issuer</b></font><br><font style="font-family: Times New Roman; font-size: 12pt"><b>Pursuant
      to Rule 13a-16 under</b></font><br>t<font style="font-family: Times New Roman; font-size: 12pt"><b>he
      Securities Exchange Act of 1934</b></font><br><br><br>For the month ended<font style="font-family: Times New Roman; font-size: 10pt">
      November, 2008</font><br><br><br><font style="font-family: Times New Roman; font-size: 18pt"><b>ICON&#160;plc</b></font><br>(R<font style="font-family: Times New Roman; font-size: 10pt">egistrant's
      name)</font><br><br><br>0-29714<br>(Commission file number)<br><br><br>South
      County Business Park, Leopardstown, Dublin 18, Ireland<br>(Address of
      principal executive offices)<br><br><br>
    </p>
    <p>
      Indicate by check mark whether the registrant files or will file annual
      reports under cover Form 20-F or Form 40-F.<br>
    </p>
    <p style="text-align: center">
      &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Yes___<u><b>X</b></u>___&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No___<b>_</b>___<br><br>
    </p>
    <p>
      Indicate by check mark whether the registrant is submitting the Form 6-K
      in paper as permitted by Regulation S-T Rule 101(b)(1):<br>
    </p>
    <p style="white-space: nowrap; text-align: center">
      &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Yes______&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No___<u><b>X</b></u>___<br><br>
    </p>
    <p>
      Indicate by check mark whether the registrant is submitting the Form 6-K
      in paper as permitted by Regulation S-T Rule 101(b)(7):<br>
    </p>
    <p style="white-space: nowrap; text-align: center">
      &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Yes______&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No___<u><b>X</b></u>___<br><br>
    </p>
    <p>
      Indicate by check mark whether the registrant by furnishing the
      information contained in this Form is also thereby furnishing the
      information to the Commission pursuant to Rule 12g3-2(b) under the
      Securities Exchange Act of 1934.<br>
    </p>
    <p style="white-space: nowrap; text-align: center">
      &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Yes___<b>_</b>___&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No___<u><b>X</b></u>___<br><br>
    </p>
    <p style="white-space: nowrap">
      If &quot;Yes&quot; is marked, indicate below the file number assigned to the
      registrant in connection with Rule 12g3-2(b):82&#160;&#160;&#160;&#160;&#160;&#160;<b>N/A</b><br><br>
    </p>
    <div style="width: 100%; margin-right: 0pt; text-indent: 0pt; margin-bottom: 10pt; margin-left: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="text-align: center">
      <u><font style="font-size: 10pt"><b>EXHIBIT&#160;LIST</b></font></u><br>
    </p>
    <div style="text-align:left">
    <table style="width: 100%; font-family: Times New Roman; font-size: 10pt; margin-bottom: 10.0px" cellspacing="0">
      <tr>
        <td style="width: 6%; text-align: left; padding-left: 0.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <u>Exhibit</u>
          </p>
        </td>
        <td style="width: 2%">
          &#160;
        </td>
        <td style="width: 20%; text-align: left; padding-left: 0.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <u>Description</u>
          </p>
        </td>
        <td style="width: 72%">

        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 2%">

        </td>
        <td style="width: 20%">

        </td>
        <td style="width: 72%">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="width: 6%; text-align: left; padding-left: 0.0px; padding-right: 0.0px; white-space: nowrap" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            99.1
          </p>
        </td>
        <td style="width: 2%">

        </td>
        <td style="text-align: left; padding-left: 0.0px" colspan="2" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Icon plc Press Release
          </p>
        </td>
      </tr>
    </table>
    </div>
    <div style="margin-right: 0pt; width: 100%; text-indent: 0pt; margin-bottom: 10pt; margin-left: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="text-align: center">
      <br>

    </p>
    <p style="text-align: center">
      <font style="font-size: 10pt"><b>SIGNATURES</b></font>
    </p>
    <p>
      <font style="font-family: Times New Roman; font-size: 10pt">Pursuant to
      the requirements of the Securities Exchange Act of 1934, the registrant
      has duly caused this report to be signed on its behalf by the
      undersigned hereunto duly authorized.</font>
    </p>
    <div style="text-align:left">
    <table style="width: 100%; font-family: Times New Roman; font-size: 10pt; margin-bottom: 10.0px" cellspacing="0">
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 55%">

        </td>
        <td style="width: 40%; text-align: left; padding-left: 0.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>ICON plc</b>
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 55%">

        </td>
        <td style="width: 40%">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 55%">

        </td>
        <td style="width: 40%">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 55%">

        </td>
        <td style="width: 40%">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 55%">

        </td>
        <td style="width: 40%; text-align: left; padding-left: 0.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 5%; text-align: left; padding-left: 0.0px" valign="top">
          Date:
        </td>
        <td style="width: 55%; text-align: left; padding-left: 0.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            November 14, 2008
          </p>
        </td>
        <td style="width: 40%; text-align: left; padding-left: 0.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <u>/s/ Ciaran Murray</u>
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 55%">

        </td>
        <td style="width: 40%; text-align: left; padding-left: 0.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Ciaran Murray
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 55%">

        </td>
        <td style="width: 40%; text-align: left; padding-left: 0.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Chief Financial Officer
          </p>
        </td>
      </tr>
    </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a5831439ex99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2008 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-size: 8pt; font-family: Times New Roman">
    <p style="text-align: right">
      <b>Exhibit 99.1</b>
    </p>
    <p>
      <font style="font-family: Times New Roman; font-size: 12pt"><b>ICON
      Acquires Prevalere Life Sciences Inc</b></font>
    </p>
    <p>
      <i><font style="font-family: Times New Roman; font-size: 12pt"><b>Expands
      Bioanalytical and Immunoassay Capabilities into the United States</b></font></i>
    </p>
    <p>
      DUBLIN, Ireland--(BUSINESS WIRE)--November 14, 2008--<b>ICON plc,
      (NASDAQ:ICLR) (ISIN:IE0005711209),</b> a global provider of outsourced
      development services to the pharmaceutical, biotechnology and medical
      device industries, today announced that is has acquired Prevalere Life
      Sciences Inc., a wholly owned subsidiary of ORS Labs Inc. Under the
      terms of the agreement ICON will pay an initial cash consideration of
      $35M. If certain performance milestones are achieved, a further
      consideration, up to a maximum of $8.2M may be payable.
    </p>
    <p>
      Prevalere is one of the leading providers of bioanalytical and
      immunoassay laboratory services to the biotechnology and pharmaceutical
      industries and operates from a 49,000 square foot facility in
      Whitesboro, New York. Prevalere will complement ICON&#8217;s existing
      European-based bioanalytical lab capabilities, where ICON Development
      Solutions recently moved to a new, purpose-built bioanalytical and
      immunoassay laboratory in Manchester, England.
    </p>
    <p>
      &#8220;The acquisition of Prevalere gives ICON much greater scale in the
      rapidly growing market for bioanalytical and immunoassay laboratory
      services and adds value to our service offering in early phase clinical
      development,&#8221; commented Peter Gray, ICON CEO. &#8220;Prevalere brings to ICON
      a highly experienced team, an excellent lab facility in the United
      States and a strong market reputation amongst top-tier pharmaceutical
      and biotechnology companies.&#8221;
    </p>
    <p>
      &#8220;I am delighted that Prevalere will be joining forces with ICON to offer
      a broader range of early drug development services to our clients,&#8221; said
      Mario Rocci, CEO of Prevalere. &#8220;I believe both companies share a
      commitment to quality, customer focus and technical excellence that will
      continue to foster growth and innovation.&#8221;
    </p>
    <p>
      <b>About ICON plc</b>
    </p>
    <p>
      ICON plc is a global provider of outsourced development services to the
      pharmaceutical, biotechnology and medical device industries. The Company
      specialises in the strategic development, management and analysis of
      programs that support clinical development - from compound selection to
      Phase I-IV clinical studies. ICON teams have successfully conducted over
      5500 development projects and consultancy engagements across all major
      therapeutic areas. ICON currently has over 6600 employees, operating
      from 71 locations in 38 countries. Further information is available at <u>www.iconplc.com</u>.
    </p>
    <div style="width: 100%; margin-right: 0pt; text-indent: 0pt; margin-bottom: 10pt; margin-left: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>
      <b>About Prevalere Life Sciences, Inc</b>
    </p>
    <p>
      Prevalere Life Sciences, Inc. is a contract research organisation that
      provides consulting, bioanalytical and physical/chemical testing
      services that meet the evolving research and development challenges of
      the pharmaceutical and biotechnology industries. Further information can
      be obtained at <u>www.Prevalere.com</u>.
    </p>
    <p>

    </p>
    <p>
      CONTACT:<br>ICON plc<br>Ciaran Murray, CFO<br>+353-1-291-2000
    </p>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
